BioXcel Therapeutics (BTAI) Debt Ratio (2018 - 2026)

BioXcel Therapeutics' Debt Ratio history runs 9 years deep, the most recent figure standing at 2.95 for Q1 2026.

• In Q1 2026, Debt Ratio rose 7.72% year-over-year to 2.95; the TTM figure through Mar 2026 stood at 2.95 (up 7.72% YoY), while the FY2025 annual figure was 2.44, down 8.74% from the prior year.
• Debt Ratio was 2.95 for Q1 2026 at BioXcel Therapeutics, up from 2.44 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 4.21 in Q2 2025 to a low of 0.0 in Q1 2022.
• Historically, Debt Ratio has averaged 1.59 across 5 years, with a median of 1.36 in 2023.
• The sharpest annual moves came in 2023 and 2025: Debt Ratio surged 199612.67% in 2023, then decreased 8.74% in 2025.
• A 5-year view of Debt Ratio shows it stood at 0.45 in 2022, then soared by 200.59% to 1.36 in 2023, then surged by 95.89% to 2.67 in 2024, then decreased by 8.74% to 2.44 in 2025, then advanced by 20.8% to 2.95 in 2026.
• The last three Debt Ratio figures came in at 2.95 (Q1 2026), 2.44 (Q4 2025), and 2.44 (Q3 2025), per Business Quant data.